Explore daily insights on
Enliven Therapeutics Surges 14.3% on FDA Alignment for Leukemia Trial
- Enliven Therapeutics surged after reaching an agreement with the US FDA on the dose recommendation for its late-stage Chronic Myeloid Leukemia trial.
- The stock rose 14.30% to close at $46.13 on volume that was 5.96 times its 20-day average.
- The regulatory alignment clears the path for the company to initiate its Phase 3 study, boosting investor confidence in its clinical pipeline.
Supporting datasets
Supporting queries
To surface this insight, Baselight ran 4 queries across its structured data. Each one is reproducible — open it, read the SQL, and rerun it yourself.
Conclusion
ELVN close rose from $40.36 on June 11 to $46.13 on June 12 (+14.30%) on 6,144,062 shares (vs. 20-day average of 1,031,674).